NCT03873324View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of CPL500036 Compound in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

December 20, 2018

Primary Completion Date

September 16, 2019

Study Completion Date

September 16, 2019

Conditions

Healthy Volunteers

Interventions

DRUG

CPL500036 compound

IMP is a capsule with CPL500036 as an Active Pharmaceutical Ingredient (API).

DRUG

Placebo

matching placebo capsules

Trial Locations (1)

05-830

BioResearch Group Sp. z o.o., Kajetany

Sponsors

Lead Sponsor

Celon Pharma SA

All Listed Sponsors

collaborator

National Center for Research and Development, Poland

OTHER

lead

Celon Pharma SA

INDUSTRY